Purple Biotech Announces 1-for-10 Reverse ADS Split to Regain Nasdaq Compliance
Summary
Purple Biotech announced a 1-for-10 reverse ADS split, effective March 2, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.
Key Events
-
ADS Ratio Change Announced
Purple Biotech will change its American Depositary Share (ADS) ratio from 1 ADS representing 200 ordinary shares to 1 ADS representing 2,000 ordinary shares.
-
Effective Date
The ADS Ratio Change is expected to become effective at the beginning of trading on or about March 2, 2026.
-
Purpose for Nasdaq Compliance
The primary purpose of this change is to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
-
Impact on ADS Holders
For ADS holders, this change will have the same effect as a one-for-ten reverse ADS split. Fractional new ADSs will not be issued; instead, cash proceeds from their sale will be distributed.
Analysis
Purple Biotech is implementing a 1-for-10 reverse ADS split, effective March 2, 2026, by changing its ADS ratio. This action is a critical step for the company to regain compliance with Nasdaq's minimum bid price requirement, thereby preventing a potential delisting. While necessary for continued listing, reverse splits are generally viewed negatively by the market as they often signal underlying financial or operational challenges that led to a depressed share price. Investors should monitor the company's ability to maintain its share price above the Nasdaq threshold post-split and assess its long-term operational performance.
At the time of this filing, PPBT was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.46 to $3.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.